soul trial oral semaglutide cardiovascular outcomes results 2025 New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj and (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis Canadian Perspectives 2025 Whiteboard on

Activation of AMPK by GLP-1R agonists mitigates alzheimer-related phenotypes in transgenic mice

Lyophilized: Store at 20 C (4 F) in dry, dark conditions [9]

Brand-name manufacturers like Novo Nordisk operate under stringent FDA Current Good Manufacturing Practices with extensive quality control testing on every batch

Retatrutide latest research's unique triple agonist mechanism creates a hostile metabolic environment for cancer cells while preserving normal tissue function

Patients must consult a licensed endocrinologist, diabetologist, or primary care physician before starting, changing, or stopping semaglutide therapy

Retatrutide, an investigational triple agonist that adds glucagon receptor activation, now points toward what may be the next benchmark